RPRX (Royalty Pharma) Buildings And Improvements: $0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

RPRX Royalty Pharma PLC RPRX
75 GF Score
Price $58.47
GF Value $42.76
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Royalty Pharma Buildings And Improvements?

Royalty Pharma RPRX -0.98% 75 Buildings And Improvements is $0 Mil as of Jun. 2026. GuruFocus rates RPRX with a GF Score™ of 75/100 and a GF Value™ of $42.76 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Royalty Pharma Buildings And Improvements Historical Data

* Premium members only.

The historical data trend for Royalty Pharma's Buildings And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Royalty Pharma Buildings And Improvements Chart

Royalty Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buildings And Improvements
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 0.00 0.00 0.00

Royalty Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Buildings And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
RPRX
75GF Score
Royalty Pharma PLC RPRX
Buildings And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Royalty Pharma Buildings And Improvements Calculation

Buildings are typically valued at the time of acquisition or construction.  Broker and architect fees, permits, etc. can be covered within this category.  Building components, such as a roof, are normally recorded separately in an asset register since the value and useful lives of these components equal much less than the building itself.

Building improvements that extend the useful life of a building will fall into the category of “building improvements” and should be capitalized.  Improvements are commonly recorded at acquisition cost.  Building improvement examples include roofing, remodeling, replacements, etc.

What does a Buildings And Improvements of $0 Mil mean?
Royalty Pharma (RPRX) has a Buildings And Improvements of $0 Mil as of Jun. 2026. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Royalty Pharma and its competitors.
Is Royalty Pharma's Buildings And Improvements too high?
Royalty Pharma's current Buildings And Improvements is $0 Mil. Overall, Royalty Pharma has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Royalty Pharma's Buildings And Improvements compare to INSM and BNTX?
Royalty Pharma's Buildings And Improvements of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buildings And Improvements for a Biotechnology company?
A good Buildings And Improvements depends on the Biotechnology industry context. However, Buildings And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buildings And Improvements mean?
A high Buildings And Improvements can signal that a stock is expensive relative to its fundamentals. Buildings and improvements is the total value of a company's buildings and improvements to them. View historical data on Royalty Pharma and its competitors. Royalty Pharma's current Buildings And Improvements is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Royalty Pharma stock overvalued right now?
Based on GuruFocus' analysis, Royalty Pharma (RPRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $42.76, compared to a current price of $58.47 — trading 36.7% above its estimated fair value. The current Buildings And Improvements is $0 Mil. Royalty Pharma's overall GF Score™ is 75/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buildings And Improvements calculated?
Buildings And Improvements is calculated from a company's financial statements. For Royalty Pharma (RPRX), the current Buildings And Improvements is $0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Royalty Pharma (RPRX) Overvalued in 2026?

Based on GuruFocus' analysis, Royalty Pharma stock appears to be overvalued. The current stock price of $58.47 is trading 36.7% above its estimated GF Value™ of $42.76. GuruFocus considers Royalty Pharma to be Significantly Overvalued.

Key valuation signals for RPRX:

  • Buildings And Improvements: $0 Mil
  • GF Value™: $42.76 vs. price of $58.47 (36.7% above fair value)
  • GF Score™: 75/100 with 9 warning signs

No single metric tells the full story. See the RPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Royalty Pharma Business Description

Other Exchanges RPD:Germany
Address 110 East 59th Street, New York, NY, USA, 10022
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
75GF Score

Get the complete analysis for RPRX

Buildings And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$58.47
Price
$42.76
GF Value